Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: A pilot study

Samir K. Gupta, Raymond M. Johnson, Chandan Saha, Kieren J. Mather, Martha L. Greenwald, Jeffrey S. Waltz, Jalees Rehman, Michael P. Dubé

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

We hypothesized that heightened systemic inflammation contributes to the increased rate of cardiovascular events in HIV-infected patients not receiving combination antiretroviral therapy. We performed a pilot trial to assess the effects of the nuclear factor-κB inhibitor salsalate on flow-mediated dilation of the brachial artery, a measure of endothelial function. Flow-mediated dilation significantly improved after 8 weeks of salsalate. However, hepatotoxicity occurred frequently. Research using alternative agents is warranted to examine the role of inflammation in HIV-related cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)653-655
Number of pages3
JournalAIDS
Volume22
Issue number5
DOIs
StatePublished - Mar 2008

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: A pilot study'. Together they form a unique fingerprint.

  • Cite this

    Gupta, S. K., Johnson, R. M., Saha, C., Mather, K. J., Greenwald, M. L., Waltz, J. S., Rehman, J., & Dubé, M. P. (2008). Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: A pilot study. AIDS, 22(5), 653-655. https://doi.org/10.1097/QAD.0b013e3282f470d2